

REFERENCES

1. **Tomi, N. and Luger, TA. (2003):** The treatment of atopic dermatitis with topical immunomodulators. Elsevier Inc; 21:215-224.
2. **Rosenfeldt, V.; Michaelsen, F.; Jakobsen, J. et al., (2002):** Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of non-hospitalized children attending day care centers. *Pediatr Infect Dis J*; 21:417-9.
3. **Kemp, AS. (2003):** Cost of illness of atopic dermatitis in children: a social perspective. *Pharmacoeconomics*; 21(2): 105-13.
4. **Wadonda-Kabondo, N.; Sterne, JAC.; Golding, J. et al., (2003):** A prospective study of the prevalence and incidence of atopic dermatitis in children aged 0– 42 months. *Br J Dermatol*;149 (5):1023–8.
5. **Taylor AL.; Dunstan JA. and Prescott SL. (2007):** Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: A randomized controlled trial. *J Allergy Clin Immunol*; 119: 184-91.
6. **Prescott SL. (2003):** Early origins of allergic disease: a review of processes and influences during early immune development. *Curr Opin Allergy Clin Immunol*; 3: 125-32.
7. **Williams, H.; Robertson, C. and Stewart, A. (1999):** Worldwide variation in the prevalence of atopic eczema symptoms. *J Allergy Clin Immunol*; **103**: 125-138.
8. **Bieber, T. (2008):** Mechanisms of disease: Atopic dermatitis. *N Engl J Med*; **358**:1483-94.

9. **Rudikoff, D. and Lebwohl, M. (1998):** Atopic dermatitis. *Lancet*; 351:1715–21.
10. **Hoffjan, S. and Epplen, J. (2005):** The genetics of atopic dermatitis: recent findings and future options. *J Mol Med*; **83**:682–92.
11. **Lee, Y.; Wahn, U.; Kehrt, R. et al., (2000):** A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. *Nat Genet*; **26**:470–3.
12. **Cookson, W.; Ubhi, B.; Lawrence, R. et al., (2001):** Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. *Nat Genet*; **27**:372–3.
13. **Haagerup, A.; Bjerke, T.; Schiotz, P. et al., (2004):** Atopic dermatitis—a total genome-scan for susceptibility genes. *Acta Derm Venereol*; **84**:346–52.
14. **Schmid-Ott, G.; Jaeger, B.; Adamek, C. et al., (2001):** Levels of circulating CD8+ T-lymphocytes, natural killer cells and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. *J Allergy Clin Immunol*; **107**:171–7.
15. **Toyoda, M.; Nakamura, M.; Makino, T. et al., (2002):** Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. *Br J Dermatol*; **147**:71–9.
16. **Raap, U.; Goltz, C.; Deneka, N. et al., (2005):** Brain-derived neurotrophic factor is increased in atopic eczema and modulates eosinophil functions compared with that seen in nonatopic subjects. *J Allergy Clin Immunol*; **115**:1268–75.
17. **Swami, S. (2008):** Atopic Dermatitis. [www . DCMS online . org](http://www.DCMSonline.org); **59**: (2) 23 - 25.

References

18. **Sampson, H. (2004):** Update on food allergy. *J Allergy Clin Immunol*; **113**:805–19.
19. **Werfel, T. and Breuer, K. (2004):** Role of food allergy in atopic dermatitis. *Curr Opin Allergy Clin Immunol*; **4**:379–85.
20. **Leung, D. (2003):** Infection in atopic dermatitis. *Curr Opin Pediatr*; **15**:399– 404.
21. **Hauk, P. and Leung, D. (2001):** Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis?. *J Allergy Clin Immunol*; **107**:391–2.
22. **Ong, P.; Ohtake, T.; Brandt, C. et al., (2002):** Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med*; **347**:1151– 60.
23. **Nomura, I.; Goleva, E.; Howell, M. et al., (2003):** Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. *J Immunol*; **171**:3262–9.
24. **Howell, M.; Wollenberg, A.; Gallo, R. et al., (2006):** Cathelicidin deficiency predisposes to eczema herpeticum. *J Allergy Clin Immunol*; **117**:836–41.
25. **Scheynius. A.; Johansson, C.; Buentke, E. et al., (2002):** Atopic eczema/ dermatitis syndrome and *Malassezia*. *Int Arch Allergy Immunol*; **127**:161–9.
26. **Schmid-Grendelmeier, P.; Scheynius, A. and Cramer, R. (2006):** The role of sensitization to *Malassezia sympodialis* in atopic eczema. *Chem Immunol Allergy*; **91**:98–109.
27. **Mothes, N.; Niggemann, B.; Jenneck, C. et al., (2005):** The cradle of IgE hyperreactivity in atopic eczema lies in infancy. *J Allergy Clin Immunol*; **116**:706–9.

28. **Schmid-Grendelmeier, P.; Fluckiger, S.; Disch, R. et al., (2005):** IgE-mediated and T cellmediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. *J Allergy Clin Immunol*; **115**:1068–75.
29. **Novak, N.; Bieber, T. and Leung, D. (2003):** Immune mechanisms leading to atopic dermatitis. *J Allergy Clin Immunol*; **112**(1):128–39.
30. **Leung, D.; Boguniewicz, M.; Howell, M. et al., (2004):** New insights into atopic dermatitis. *J Clin Invest*; **113**:651–7.
31. **Toda, M.; Leung, D.; Molet, S. et al., (2003):** Polarized in vivo expression of IL-11 and Il-17 between acute and chronic skin lesions. *J Allergy Clin Immunol*; **111**:875–81.
32. **Hijnen, D.; De Bruin-Weller, M.; Oosting, B. et al., (2004):** Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. *J Allergy Clin Immunol*; **113**:334–40.
33. **Echigo, T.; Hasegawa, M.; Shimada, Y. et al., (2004):** Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. *J Allergy Clin Immunol*; **113**: 940–8.
34. **Novak, N. and Bieber, T. (2003):** Allergic and nonallergic forms of atopic diseases. *J Allergy Clin Immunol*; **112**:252–62.
35. **Kerschenlohr, K.; Decard, S.; Darsow, U. et al., (2003):** Clinical and immunologic reactivity to aeroallergens in –intrinsic- atopic dermatitis patients. *J Allergy Clin Immunol*; **111**:195–7.
36. **Novak, N.; Tepel, C.; Koch, S. et al., (2003):** Evidence for a differential expression of the Fcepsilon RI gamma chain in dendritic cells of atopic and nonatopic donors. *J Clin Invest*; **111**:1047–56.

References

37. **Baud, O.; Goulet, O.; Canioni, D. et al., (2001):** Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. *N Engl J Med*; **344**:1758–62.
38. **Akdis, C.; Blaser, K. and Akdis, M. (2004):** Apoptosis in tissue inflammation and allergic disease. *Curr Opin Immunol*; **16**:717–23.
39. **Lin, W.; Truong, N.; Grossman, W. et al., (2005):** Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. *J Allergy Clin Immunol*; **116**:1106-15.
40. **Ou, L.; Goleva, E.; Hall, C. et al., (2004):** T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. *J Allergy Clin Immunol*; **113**:756–63.
41. **Novak, N.; Valenta, R.; Bohle, B. et al., (2004):** FcεRI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. *J Allergy Clin Immunol*; **113**:49–57.
42. **Grewe, M.; Czech, W.; Morita, A. et al., (1998):** Human eosinophils produce biologically active IL-12: implications for control of T cell responses. *J Immunol*; **161**:15–20.
43. **Simon, D.; Braathen, L. and Simon, H. (2004):** Eosinophils and atopic dermatitis. *Allergy*; **59**:561-70.
44. **Obara, W.; Kawa, Y.; Ra, C. et al., (2002):** T cells and mast cells as a major source of interleukin-13 in atopic dermatitis. *Dermatol*; **205**:11-7.

References

45. **Sayama, K.; Komatsuzawa, H.; Yamasaki, K. et al., (2005):** New mechanisms of skin innate immunity: ASK1-mediated keratinocyte differentiation regulates the expression of b-defensins, LL37, and TLR2. *Eur J Immunol*; **35**:1886-95.
46. **Giustizieri, M.; Mascia, F.; Frezzolini, A. et al., (2001):** Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. *J Allergy Clin Immunol*; **107**:871-7.
47. **Yoo, J.; Omori, M.; Gyarmati, D. et al., (2005):** Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. *J Exp Med*; **202**:541-9.
48. **Trautmann, A.; Akdis, M.; Kleeman, D. et al., (2000):** T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. *J Clin Invest*; **106**:25-35.
49. **Pastore, S.; Corinti, S.; La-Placa, M. et al., (1998):** Interferongamma promotes exaggerated cytokine production in keratinocytes cultured from patients with atopic dermatitis. *J Allergy Clin Immunol*; **101**:538-44.
50. **Trautmann, A.; Altnauer, F.; Akdis, M. et al., (2001):** The differential fate of cadherins during T cell-induced keratinocyte apoptosis leads to spongiosis in eczematous dermatitis. *J Invest Derm*; **117**:927-34.
51. **Sator, P.; Schmidt, J. and Honigsmann, H. (2003):** Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. *J Am Acad Dermatol*; **48**:352-8.

References

52. **Sugiura, H.; Ebise, H.; Tazawa, T. et al., (2005):** Large scale DNA microarray analysis of atopic skin lesions showing over expression of an epidermal differentiation gene cluster in alternative pathway and lack of protection gene expression in cornified envelop. *Br J Dermatol*; **152**: 146-9.
53. **Hoffjan, S. and Stemmler, S. (2007):** The role of epidermal differentiation complex in ichthyosis vulgaris, AD and psoriasis. *Br J Dermatol*; **157**: 441-9.
54. **Rippke, F.; Schreiner, V.; Doering, T. et al., (2004):** Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with *Staphylococcus aureus*. *Am J Clin Dermatol*; **5**:217-23.
55. **Farhi, D.; Taieb, A.; Tilles, G. et al., (2010):** The historical basis of a misconception leading to undertreating A.D: Facts and controversies. *Clinics in Dermatol*; **28**: 45-51.
56. **Shimizu, H (2007):** Text book of dermatology. **11:9** (99-102).
57. **Yuwalker, N.; Uguccloni, M.; Scharer, J. et al., (1999):** Enhanced expression of eotaxin and CCR3 in atopic dermatitis. *J Invest Dermatol*; **113**:43-8.
58. **Niwa, Y. (2000):** Elevated RANTES levels in plasma or skin decreased plasma IL-10 levels in subsets of patients with severe atopic dermatitis. *Arch Dermatol*; **136**:125-6.
59. **Laughter, D.; Istvan, J. Tofte, S. et al., (2000):** The prevalence of atopic dermatitis in Oregon schoolchildren. *J Am Acad Dermatol*; **43**:649-55
60. **Sugiura, H.; Umemoto, N.; Deguchi, H. et al., (1998):** Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. *Acta Derm Venereol*; **78**:293-4.

References

61. **Eichenfield, L.; Hanifin, J.; Beck, L. et al., (2003):** Atopic dermatitis and asthma: parallels in the evolution of treatment. *Pediatrics*; **111**:608-16.
62. **Williams, H. and Strachan, D. (1998):** The natural history of childhood eczema: observations from the British 1958 birth cohort study. *Br J Dermatol*; **139**:834-9.
63. **Eichenfield, L.; Hanifin, J.; Luger, T. et al., (2003):** Consensus conference on pediatric atopic dermatitis. *J Am Acad Dermatol*; **49**:1088–95
64. **Gustafsson, D.; Sjoberg, O. and Foucard, T. (2000):** Development of allergies and asthma in infants and young children with atopic dermatitis: a prospective follow-up to 7 years of age. *Allergy*; **55**:240-5.
65. **Wuthrich, B. (1999):** Clinical aspects, epidemiology, and prognosis of atopic dermatitis. *Ann Allergy Asthma Immunol*; **83**:464-70.
66. **Gdalevich, M.; Minouni, D.; David, M. et al., (2001):** Breast-feeding and the onset of atopic dermatitis in childhood: A systematic review and meta-analysis of prospective studies. *J Am Acad Dermatol*; **45**:520-527.
67. **Arkwright, P.; Patel, L. and David, T. (1998):** Dietary management of atopic eczema: is this justified? *Hospit Med*; **59**: 690-692.
68. **Yesudian, P. and Sharp, G. (2003):** The management of eczema in children. *Current Paediatrics*; **13**: 413—417.
69. **Seidenari, S.; Giusti, F.; Pellicani, G. et al., (2003):** Frequency and intensity of responses to mite patch tests are lower in non atopic subjects in respect to patients with atopic dermatitis. *Allergy*; **58**: 426–429.

70. **Mortz, C. and Andersen, K. (1999):** Allergic contact dermatitis in children and adolescents. *Contact Dermatitis*; **41**: 121–130.
71. **Tabata, N.; Tagami, H. and Kligman, A. (1998):** A twenty-four-hour occlusive exposure to 1% sodium lauryl sulfate induces a unique histopathologic inflammatory response in the xerotic skin of atopic dermatitis patients. *Acta Derm Venereol*; **78**:244-7.
72. **Breneman, D.; Hanifin, J.; Berge, C. et al., (2000):** The effect of antibacterial soap with 1.5% triclocarban on *Staphylococcus aureus* in patients with atopic dermatitis. *Cutis*; **66**:296-300.
73. **Macheleidt, O.; Kaiser, H. and Sandhoff, K. (2002):** Deficiency of epidermal protein- bound omega-hydroxyceramides in atopic dermatitis. *J Invest Dermatol*; **119**:166-73.
74. **Arika-wa, J.; Ishibashi, M.; Kawashima, M. et al., (2002):** Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by *Staphylococcus aureus*. *J Invest Dermatol*; **119**:433-9.
75. **De Paepe, K.; Hachem, J.; Vanpee, E. et al., (2002):** Effect of rice starch as a bath additive on the barrier function of healthy but Ls damaged skin and skin of atopic patients. *Acta Derm Venereol*; **82**:184-6.
76. **Tabata, N.; O’Goshi, K.; Zhen, Y. et al., (2000):** Biophysical assessment of persistent effects of moisturizers after their daily applications: evaluation of corneotherapy. *Dermatology*; **200**:308-13.
77. **Anthony, J.; O’lenick, J. and Siltech, L. (2009):** Comparatively speaking: Humectant vs. Emollients vs. Occlusive agents. *J Am Acad Dermatol*; **100**: 25-30.

References

78. **Barnes, P. (2000):** New directions in allergic diseases: mechanism-based antiinflammatory therapies. *J Allergy Clin Immunol*; **106**:5-16.
79. **Long, C.; Mills, C. and Finlay, A. (1998):** A practical guide to topical therapy in children. *Br J Dermatol*; **138**:293-6.
80. **Friedlander, S.; Hebert, A. and Allen, D. (2002):** Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. *J Am Acad Dermatol*; **46**:387-93.
81. **Carnahan, M and Goldstein, D. (2000):** Ocular complications of topical, peri-ocular, and systemic corticosteroids. *Curr Opin Ophthalmol*; **11**:478–83.
82. **Schoopf, R. (2002):** Pimecrolimus. *Curr Opin Investig Drugs*; **3**:720–4.
83. **Boguniewicz, M.; Fiedler, V.; Raimer, S. et al., (1998):** A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children: Pediatric Tacrolimus Study Group. *J Allergy Clin Immunol*; **102**(4):637–44.
84. **Kang, S.; Lucky, A.; Pariser, D. et al., (2001):** Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. *J Am Acad Dermatol*; **44**(1):S58–64.
85. **Paller, A. Eichenfield, L. Leung, D. et al., (2001):** A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. *J Am Acad Dermatol*; **44**(1):47–57.
86. **Remitz A, Kyllonen H, Granlund H, et al., (2001):** Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. *J Allergy Clin Immunol*; **107**:196–7.

References

87. **Luger, T.; Van Leent, E.; Graeber, M. et al., (2001):** SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. *Br J Dermatol*; **144**:788–94.
88. **Paller, A.; Hedgecock, S.; Marshall, K. et al., (2001):** Elidel: superior efficacy and safety in infants and children with atopic dermatitis. *Pediatr Dermatol*; **18(I)**:133.
89. **Wahn, U.; Bos, J.; Goodfield, M. et al., (2002):** Efficacy and Safety of Pimecrolimus Cream in Long-Term Management of Atopic Dermatitis in Children. *Pediatrics*; **110**:1–8.
90. **Hanifin, J.; Cooper, K.; Ho, V. et al., (2004):** Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines.” *J Am Acad Dermatol*; **50**:391-404.
91. **Harper, J.; Ahmed, I.; Barclay, G. et al., (2000):** Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. *Br J Dermatol*; **142**: 52-8.
92. **Grundmann-Kollmann, M.; Podda, M.; Ochsendorf, F. et al., (2001):** Mycophenolate mofetil is effective in the treatment of atopic dermatitis. *Arch Dermatol*; **137**:870-3.
93. **Berth-Jones, J.; Takwale, A.; Tan, E. et al., (2002):** Azathioprine in severe adult atopic dermatitis: a doubleblind, placebo-controlled, crossover trial. *Br J Dermatol*; **147**:324-30.
94. **Murphy, LA. and Atherton, D. (2002):** A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. *Br J Dermatol*; **147**:308-15.

References

95. **Schneider, L.; Baz, Z.; Zarccone, C. et al., (1998):** Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. *Ann Allergy Asthma Immunol*; **80**:263-8.
96. **Jang, I.; Yang, J.; Lee, H. et al., (2000):** Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. *J Am Acad Dermatol*; **42**:1033-40.
97. **Lathouder, S.; Gerards, A.; Groot, E. et al., (2002):** Mycophenolic acid and methotrexate inhibit lymphocyte cytokine production via different mechanisms. *Eur Cytokine Netw*; **13**:317–23.
98. **Callen, J. Kulp-Shorten, C. and Wolverton, S. (2001):** Methotrexate. In: Wolverton SE, editor. *Comprehensive Dermatologic Drug Therapy*. Philadelphia: W. B. Saunders; 147–164.
99. **Sidbury, R. and Hanifin, J. (2000):** Systemic therapy of atopic dermatitis. *Clin Exp Dermatol*; **25**:559–66.
100. **Capella, G.; Grigerio, E. and Altomare, G. (2001):** A randomized trial of leukotriene receptor antagonist montelukast in moderate to-severe atopic dermatitis of adults. *Eur J Dermatol*; **11**:209-13.
101. **Yanase, D. and David-Bajar, K. (2001):** The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. *J Am Acad Dermatol*; **44**:89-93.
102. **Jolles, S. (2002):** A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. *Clin Exp Dermatol*; **27**:3-7.
103. **Bratton, D.; May, K. and Kailey, J. (1999):** Staphylococcal toxic shock syndrome toxin-1 inhibits monocyte apoptosis. *J Allergy Clin Immunol*; **103**:895-900.

References

104. **Skov, L.; Olsen, J.; Giorno, R. et al., (2000):** Application of staphylococcal enterotoxin B on normal and atopic cells induces up-regulation of T cells by a superantigen-mediated mechanism. *J Allergy Clin Immunol*; **105**:820-6.
105. **Abeck, D and Mempel, M. (1998):** Staphylococcal aureus colonization in atopic dermatitis and its therapeutic implications. *Br J Dermatol*; **139**:13-6.
106. **Reynolds, N.; Franklin, V.; Gray, J. et al., (2001):** Narrowband ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomized controlled trial. *Lancet*; **357**:2012-6.
107. **Morris, A. and Saihan, E. (2002):** Maintenance psoralen plus ultraviolet A therapy: does it have a role in the treatment of severe atopic eczema?. *Br J Dermatol*; **146**:705-7.
108. **Leyden, J and Kligman, A. (1977):** The case for steroid-antibiotic combinations. *Br J Dermatol*; **96**:179-87.
109. **Ainley-Walker, P.; Patel, L. and David, T. (1998):** Side to side comparison of topical treatment in atopic dermatitis. *Arch Dis Child*; **79**:149-52.
110. **Torok, H.; Maas-Irslinger, R. and Slayton RM. (2003):** Clotocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. *Cutis*; **72**:161-6.
111. **Gemmill, R. and Idell, C. (2003):** Biological advances for new treatment approaches. *Seminars in Oncology Nursing*; **19 (3)**: 162–168.
112. **Greten, T. and Jaffee, E. (1999):** Cancer vaccines. *J Clin Oncol*; **17**:1047-60.

References

113. **Restifo, N. and Lewis, J. (2005):** Therapeutic vaccines. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins., 2846-2856.
114. **Kay, A. (1993):** Position paper on allergen immunotherapy: report of a British Society for Allergy and Clinical Immunology Working Party. Clin Exp Allergy; 23(3):19-22.
115. **Bosquet, J.; Lockey, R. and Malling, H. (1998):** Allergy immunotherapy: Therapeutic vaccines for allergic diseases. WHO position paper. J Allergy Clin Immunol; 102:558–562.
116. **Bush, R. and Ritter, M. (1992):** Allergen immunotherapy for the allergic patient. Immunol Allergy Clin North Am; 12:107–124.
117. **Bast, R.; Zalutsky, M.; Kreitman, R. et al., (2006):** Monoclonal serotherapy. In: (Kufe DW, Bast RC, eds.) Cancer Medicine 7. Hamilton, Ontario: BC Decker, Inc., 770-785.
118. **Hu,W.; Chau, D.; Wu, J. et al., (2007):** Humanization and mammalian expression of murine monoclonal antibody against venezuelan equine encephalitis virus; 25(16): 3210-3214.
119. **Dudley, M.; Wunderlich, J.; Robbins, P. et al. (2002):** Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science; 298:850-854.
120. **Mark, V. (2008):** Rituximab Improves Atopic Dermatitis. J Allergy Clin Immunol; 121:122.
121. **Rhona, S. and Goldenberg, D. (2004):** A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther; 3(12):1559–64.

References

122. **Terpe, K. (2003):** Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol; 60(5):523-33.
123. **Ekmekcioglu, S.; Grimm, E., Kurzrock, R. et al., (2006):** Cytokines and hematopoietic growth factors. In: (Kufe DW, Bast RC, Hait WN, eds.) Cancer Medicine 7. Hamilton, Ontario: BC Decker, Inc; 744-769.
124. **Salgaller, M. and Lodge, P. (1998):** Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol; **68**: 122–138.
125. **Hodge, W.; Schlom, J. and Abrams, S. (2006):** Vaccines and immunostimulants. In: (Kufe D, Bast R, Hait W, Hong W, eds), Cancer Medicine 7. Hamilton, Ontario: BC Decker, Inc; 786-801.
126. **Chesney, J.; Rasku, M.; Clem, A. et al., (2006):** Denileukin diftitox depletes T regulatory cells and causes regression of melanoma metastases in humans [abstract]. Eur J Cancer Suppl; 4(12):84.
127. **Pardoll, D. (1998):** Cancer vaccines. Nat Med; **4**:525-31.
128. **Hsueh EC, Nathanson, L. Foshag, L. et al., (1999):** Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer; **85**:2160-2169.
129. **Simons, J.; Jaffee, E.; Weber, C. et al., (1997):** Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res; **57**:1537-46.
130. **Repmann, R.; Wagner, S. and Richter, A. (1997):** Adjuvant therapy of renal cell carcinoma with active-specific- immunotherapy (ASI) using autologous tumor vaccine. Anticancer Res; **17**:2879-82.

References

131. **Lernmark, A. and Agardh, C. (2005):** Immunomodulation with human recombinant autoantigens. *Trends Immunol*; **26**: 608–612.
132. **Banchereau, J. and Palucka, A.K. (2005):** Dendritic cells as therapeutic vaccines against cancer. *Nat Rev Immunol*; **5**: 296–306.
133. **Widera, G.; Austin, M.; Rabussay, D. et al., (2000):** "Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo". *The Journal of Immunology*; **164** (9): 4635–4640.
134. **Betsi, G.; Papadavid, E.; and Falagas, M. (2008):** probiotics for the Treatment or Prevention of Atopic Dermatitis: A Review of the Evidence from Randomized Controlled Trials. *American Journal of Clinical Dermatology*; **9**(2):93–103.
135. **Lilly, DM. and Stillwell, RH. (1965):** Probiotics: Growth promoting factors produced by microorganisms. *Sci*; **147**: 747–748. quoted from **Vaarala, O. (2003):** Immunological effects of probiotic with special reference to lactobacilli. *Clin Exp Allergy*; **33**: 1634–1640.
136. **Fuller, R. (1989):** Probiotics in man and animals A REV.J. of Appl. Bacteriol; **66**:365–378. quoted from **Koop-Hoolihan, L. (2001):** Prophylactic and therapeutic uses of probiotics. A rev J of the Am Dietetic Assoc; **4**(2): 365–378.
137. **Krutmann, J. (2009):** Pre- and probiotics for human skin. *J of Dermatol Sci*; **54**: 1–5.
138. **Donohue. DC.; Salminen, S. and Marteau, P. (1998):** Safety of probiotic bacteria. In lactic acid bacteria eds. Salminen S, von Wright A. New York: Marcel Dekker; 369–383.
139. **Schrezenmeir, J. and De-Vrese, M. (2001):** Probiotics, prebiotics and synbiotics: approaching a definition. *Am J Clinical Nutr*; **73** (2):361S–364S.

140. www.costlessvitamin.com/.../aloecaps-tb.jpg.
141. www.Coevolv.Com/images/newchapter.Jpg.
142. [www.Naturalypure.Com/probiotics support. Htm](http://www.Naturalypure.Com/probiotics%20support.Htm).
143. **Fric, P. (2007):** Probiotics and prebiotics-renaissance of a therapeutic principle. CEJMed; 2(3): 237–270.
144. **Lestin, F.; Pertschy, A. and Rimek, D. (2003):** “Fungemia after oral treatment with *Saccharomyces boulardii* in a patient with multiple co-morbidities”, Dtsch. Med. Wschr; **128**:2531-2533.
145. **Gorbach, S.L. (2000):** “Probiotics and gastrointestinal health”, Am J Gastroenterol; **95**: S2–S4.
146. **Koop-Hoolihan, L. (2001):** Prophylactic and therapeutic uses of probiotics. A rev J of the Am Dietetic Assoc; 4(2): 365–378.
147. **Rachmilewitz, K.; Katakura, F. and Karmeli, T. (2004):** “Toll-like receptor 9 signalling mediates the antiinflammatory effects of probiotics in murine experimental colitis”, Gastroenterology; **126**: 520–528.
148. **Lee, J.; Seto, D. and Bielory, L. (2008):** Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol. **121**:116-121.
149. **Bolotin, P.; Wincker, S.; Mauger, O. et al., (2001):** “The complete genome sequence of the lactic acid bacterium *Lactococcus lactis* ssp. *lactis* IL 1403”. Genome Res; **11**: 731–753.
150. **Kleerebezem, J.; Boekhorst, R.; Van Kranenburg, D. et al., (2003):**”Complete genome sequence of *Lactobacillus plantarum* WCFS1” .Proc. NATl. Acad. Sci. USA; **100**: 1990-1995.

References

151. **Schell, M.; Karmirantzou, B.; Snel, D. et al., (2002):** Pridmore and F. Arigoni: “The genome sequence of *Bifidobacterium longum* reflects its adaptation to the human gastrointestinal tract”. *Proc. Natl. Acad. Sci. USA*; **99**: 14422–14427.
152. **Grozdanov, LC.; Raasch, J.; Schulze, U. et al., (2004):** “Analysis of the genome structure of the nonpathogenic probiotic *Escherichia coli* strain Nissle 1917”. *J Bacteriol.*; **186**: 5432–5441.
153. **Penders, J.; Stobberingh, E.; Thijs, C. et al., (2007):** Molecular fingerprinting of the intestinal microbiota of infants in whom atopic eczema was or was not developing. *Clin Exp Allergy*; **36**:1602–1608.
154. **Romagnani, S. (2006):** Regulatory T cells: which role in the pathogenesis and treatment of allergic disorders? *Allergy*; **61**:3–14.
155. **Nowak, D.; Suppli Ulrik, C.; von Mutius E. et al., (2004):** Asthma and atopy: has peak prevalence been reached? *Eur Respir J*; **23**:359–360.
156. **Noverr, MC.; Falkowski, NR.; McDonald, RA. et al., (2005):** The development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen and IL-13. *Infect Immun*; **73**:30–8.
157. **Yamanaka, T.; Helgeland, L.; Farstad, IN. et al., (2003):** Microbial colonization drives lymphocyte accumulation and differentiation in the follicle-associated epithelium of Peyer’s patches. *J Immunol*; **170**:816–22.
158. **Hooper, LV. (2004):** Bacterial contributions to mammalian gut development. *Trends Microbiol*; **12**:129–34.

References

159. **Rook, GA. and Brunet, LR. (2005):** Old friends for breakfast. *Clin Exp Allergy*; **35**:841–2.
160. **Flohr, C.; Pascoe, D. and Williams, HC. (2005):** Atopic dermatitis and the “hygiene hypothesis”: too clean to be true? *Br J Dermatol*; **152**:202–216.
161. **Wold, AE. (1998):** The hygiene hypothesis revised: is the rising frequency of allergy due to changes in the intestinal flora? *Allergy*; **53**:20–25.
162. **Bjorksten, B. (2004):** Effects of intestinal microflora and the environment on the development of asthma and allergy. *Springer Semin Immunopathol*; **25**:257–270.
163. **Prescott, S. and Bjorksten, B. (2007):** Probiotics for the prevention or treatment of allergic diseases. *J Aller Clin Immunol*; 255-262.
164. **Bjorksten, B. (2005):** Genetic and environmental risk factors for the development of food allergy. *Curr Opin Allergy Clin Immunol*; **5**:249-53.
165. **Lehmann, HS.; Heaton, T.; Mallon, D. et al., (2004):** Staphylococcal enterotoxin-B-mediated stimulation of interleukin-13 production as a potential aetiologic factor in eczema in infants. *Int Arch Allergy Immunol*; **135**:306–12.
166. **Macpherson, AJ. and Uhr, T. (2004):** Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. *Science*; **303**:1662–5.
167. **Pe´rez-Machado, MA.; Ashwood, P.; Thomson, MA. et al., (2003):** Reduced transforming growth factor-b1- producing T cells in the duodenal mucosa of children with food allergy. *Eur J Immunol*; **33**:2307–15.

References

168. **Colantonio, L.; Rossi, B.; Constantin, G. et al., (2004):** Integration and independent acquisition of specialized skin- versus gut-homing and Th1 versus Th2 cytokine synthesis phenotypes in human CD4⁺ T cells. *Eur J Immunol*; **34**:2419–29.
169. **Vries, IJ.; Langeveld-Wildschut, EG.; van Reijssen, FC. et al., (1998):** Nonspecific T-cell homing during inflammation in atopic dermatitis: expression of cutaneous lymphocyte-associated antigen and integrin α Eb7 on skin-infiltrating T cells. *J Allergy Clin Immunol*; **100**:694–701.
170. **Fuhlbrigge, RC.; Kieffer, JD.; Armerding, D. et al., (1997):** Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. *Nature*; **389**:978–81.
171. **Backhed, F.; Ley, RE.; Sonnenburg, JL. et al., (2005):** Hostbacterial mutualism in the human intestine. *Science*; **307**:1915–20.
172. **Zimmermann, N.; Doecker, MP.; Witte, DP. et al., (2005):** Expression and regulation of small proline-rich protein 2 in allergic inflammation. *Am J Respir Cell Mol Biol*; **32**:428–35.
173. **Becker, AB. (2000):** Is primary prevention of asthma possible? *Pediatr Pulmonol*; **30**:63–72.
174. **Favier, CF.; De-Vos, WM and Akkermans, AD. (2003):** Development of bacterial and bifidobacterial communities in feces of newborn babies. *Anaerobe*; **9**:219–229.
175. **Mackie, RI.; Sghir, A. and Gaskins, HR. (1999):** Developmental microbial ecology of the neonatal gastrointestinal tract. *Am J Clin Nutr*; **69**:1035S–1045S.

176. **Penders, J.; Stobberingh, EE.; vanden Brandt, PA. et al., (2007):** The role of the intestinal microbiota in the development of atopic disorders. *J compilation*; **62**: 1223-1236.
177. **Kuvaeva, IB.; Orlova, NG.; Veselova, OL. et al., (1984):** Microecology of the gastrointestinal tract and the immunological status under food allergy. *Nahrung*; **28**:689– 693. Quoted from **Prescott, S. and Bjorksten, B. (2007):** Probiotics for the prevention or treatment of allergic diseases. *J Aller Clin Immunol*; 255-262.
178. **Sepp, E.; Julge, K.; Vasar, M. et al., (1997):** Intestinal microflora of Estonian and Swedish infants. *Acta Paediatr*; **86**:956– 961.
179. **Bjorksten, B.; Naaber, P.; Sepp, E. et al., (1999):** The intestinal microflora in allergic Estonian and Swedish 2- year-old children. *Clin Exp Allergy*; **29**:342–346.
180. **Bjorksten, B.; Sepp, E.; Julge, K. et al., (2001):** Allergy development and the intestinal microflora during the first year of life. *J Allergy Clin Immunol*; **108**:516–520.
181. **Ouwehand, AC.; Isolauri, E.; He, F. et al., (2001):** Differences in Bifidobacterium flora composition in allergic and healthy infants. *J Allergy Clin Immunol*; **108**:144–145.
182. **Watanabe, S.; Narisawa, Y.; Arase, S. et al., (2003):** Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. *J Allergy Clin Immunol*; **111**:587–591.
183. **Matsumoto, M.; Ohishi, H.; Kakizoe, K. et al., (2004):** Faecal microbiota and secretory immunoglobulin A levels in adult patients with atopuic dermatitis. *Microbial Ecol Health Dis*; **16**: 13–17.

References

184. **Sepp, E.; Julge, K.; Mikelsaar, M. et al., (2005):** Intestinal microbiota and immunoglobulin E responses in 5-yearold Estonian children. *Clin Exp Allergy*; **35**:1141–1146.
185. **Kendler, M.; Uter, W.; Rueffer, A. et al., (2006):** Comparison of fecal microflora in children with atopic eczema/dermatitis syndrome according to IgE sensitization to food. *Pediatric Allergy Immunol*; **17**:141–147.
186. **Bottcher, MF.; Nordin, EK.; Sandin, A. et al., (2000):** Microfloraassociated characteristics in faeces from allergic and nonallergic infants. *Clin Exp Allergy*; **30**:1590–1596.
187. **Kirjavainen, PV.; Apostolou, E.; Arvola, T. et al., (2001):** E. Characterizing the composition of intestinal microflora as a respective treatment target in infant allergic disease. *FEMS Immunol Med Microbiol*; **32**:1–7.
188. **Kalliomaki, M.; Kirjavainen, P.; Eerola, E. et al., (2001):** Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. *J Allergy Clin Immunol*; **107**:129–134.
189. **Mah, KW.; Bjorksten, B.; Lee, BW. et al., (2006):** Distinct pattern of commensal gut microbiota in toddlers with eczema. *Int Arch Allergy Immunol*; **140**:157– 163.
190. **Linneberg, A.; Ostergaard, C.; Tvede, M. et al., (2003):** IgG antibodies against microorganisms and atopic disease in Danish adults: the Copenhagen Allergy Study. *J Allergy Clin Immunol*; **111**:847–853.
191. **Fukuda, S.; Ishikawa, H.; Koga, Y. et al., (2004):** Allergic symptoms and microflora in schoolchildren. *J Adolesc Health*; **35**:156–158.

References

192. **Penders, J.; Thijs, C.; van-den Brandt, PA. et al. (2007):** Gut microbiota composition and development of atopic manifestations in infancy: the KOALA birth cohort study. *Gut*; **56**:661–667.
193. **Banasaz, M.; Norin, E.; Holma, R. et al., (2002):** Increased enterocyte production in gnotobiotic rats mono-associated with *Lactobacillus rhamnosus* GG. *Appl Environ Microbiol*; **68**:3031–4.
194. **Christensen, HR.; Frokiaer, H. and Pestka, JJ. (2002):** Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. *J Immunol*; **168**:171–8.
195. **Pessi, T; Sutas, Y; Hurme, M. et al., (2000):** Interleukin-10 generation in atopic children following oral *Lactobacillus rhamnosus* GG. *Clin Exp Allergy*; **30**:1804–8.
196. **Miettinen, M.; Matikainen, S.; Vuopio-Varkila, J. et al., (1998):** Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. *Infect Immun*; **66**:6058–62.
197. **Miettinen, M.; Lehtonen, A.; Julkunen, I. et al., (2000):** Lactobacilli and Streptococci activate NF-kappa B and STAT signaling pathways in human macrophages. *J Immunol*; **164**:3733–40.
198. **Korhonen, R.; Korpela, R.; Saxelin, M. et al., (2001):** Induction of nitric oxide synthesis by probiotic *Lactobacillus rhamnosus* GG in J774 macrophages and human T84 intestinal epithelial cells. *Inflammation*; **25**:223–32.
199. **Solana, R. and Mariani, E. (2000):** NK and NK/T cells in human senescence. *Vaccine*; **18**:1613–20.

References

200. **Gill, HS.; Darragh, AJ. and Cross, ML. (2001):** Optimizing immunity and gut function in the elderly. *J Nutr Health Aging*; 5:80–91.
201. **Kukreja, A.; Cost, G.; Marker, J. et al., (2002):** Multiple immunoregulatory defects in type-1 diabetes. *J Clin Invest*; **109**:131–40.
202. **Fang, H.; Elina, T.; Heikki, A. et al., (2000):** Modulation of humoral immune response through probiotic intake. *FEMS Immunol Med Microbiol*; **29**:47–52.
203. **Tejada-Simon, MV.; Lee, JH.; Ustunol, Z. et al., (1999):** Ingestion of yogurt containing *Lactobacillus acidophilus* and *Bifidobacterium* to potentiate immunoglobulin A responses to cholera toxin in mice. *J Dairy Sci*; **82**:649–60.
204. **Pochard, P.; Gosset, P.; Grangette, C. et al., (2002):** Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients. *J Allergy Clin Immunol*; **110**:617–23.
205. **Cross, ML. (2002):** Microbes vs. microbes: immune signals generated by probiotic lactobacilli and their role in protection against microbial pathogens. *FEMS Immunol Med Microbiol*; **34**:245–53.
206. **Pessi, T.; Isolauri, E.; Sutas, Y. et al., (2001):** Suppression of T-cell activation by *Lactobacillus rhamnosus* GG-degraded bovine casein. *Int Immunopharmacol*; **1**:211–8.
207. **Bjorksten, B. (1999):** The intrauterine and postnatal environments. *J Allergy Clin Immunol*; **104**:1119–1127.
208. **Prescott, SL.; Macaubas, C.; Smallacombe, T. et al., (1999):** Development of allergen-specific T-cell memory in atopic and normal children. *Lancet*; **353**:196–200.

209. **Velden, VH.; Laan, MP. and Baert, MR. (2001):** Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN γ , IL-4 and IL-10. *Clin Exp Allergy*; **31**:997–1006.
210. **Gaboriau, D.; Routhiau, V.; Raibaud, P. et al., (2003):** Colonization of gnotobiotic mice with human gut microflora at birth protects against E-coli heat-labile enterotoxin-mediated abrogation of oral tolerance. *Pediatr Res*; **54**:739–746.
211. **Helin, T.; Haahtela, S. and Haahtela, T. (2002):** No effect of oral treatment with an intestinal bacterial strain, *Lactobacillus rhamnosus* (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. *Allergy*; **57**:243-6.
212. **Isolauri, E.; Arvola, T.; Sutas, Y. et al., (2000):** Probiotics in the management of atopic eczema. *Clin Exp Allergy*; **30**:1604-10.
213. **Majamaa, H. and Isolauri, E. (1998):** Probiotics: a novel approach in the management of food allergy. *J Allergy Clin Immunol*; **101**:179-85.
214. **Viljanen, M.; Savilahti, E.; Haahtela, T. et al., (2005):** Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. *Allergy*; **60**:494-500.
215. **Brouwer, M.; Wolt-Plompen, SA.; Dubois, AE. et al., (2006):** No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. *Clin Exp Allergy*; **36**:899-906.
216. **Prescott, SL.; Dunstan, JA.; Hale, J. et al., (2005):** Clinical effects of probiotics are associated with increased interferon- γ responses in very young children with atopic dermatitis. *Clin Exp Allergy*; **35**:1557-64.

References

217. **Matricardi, PM. (2002):** Probiotics against allergy: data, doubts, perspectives. *Allergy*; **20**: 57:185-7.
218. **Abrahamsson, T.; Jakobsson, T.; Boöttcher, M. et al., (2007):** Probiotics in prevention of IgE associated eczema; a double blind randomised placebo- controlled trial. *J Allergy Clin Immunol*; **119**:1174-80.
219. **Oyetayo, V.O. and Oyetayo, F.L. (2005):** Potential of probiotics as biotherapeutic agents targeting the innate immune system. *Afr J Biotechnol*; **4(2)**: 123-127.
220. **Kopp, MV.; Hennemuth, I.; Heinzmann, A. et al., (2008):** Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of lactobacillus GG supplementation. *Pediatrics*; **36**: 1204-9.